1. Home >
  2. M&A >
  3. Add-on Acquisition >
  4. United Kingdom >
  5. Lupin Acquires Renascience Pharma

M&A Deal Summary

Lupin Acquires Renascience Pharma

On April 2, 2025, Lupin acquired life science company Renascience Pharma

Acquisition Highlights
  • This is Lupin’s 9th transaction in the Life Science sector.
  • This is Lupin’s 1st transaction in the United Kingdom.

M&A Deal Summary
Date 2025-04-02
Target Renascience Pharma
Sector Life Science
Buyer(s) Lupin
Deal Type Add-on Acquisition

Target

Renascience Pharma

Luton, United Kingdom
Renascience Pharma is a pharmaceutical company specialising in niche branded products for primary and secondary care. Renascience Pharma is based in Luton, United Kingdom.

Search 214,239 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Lupin

Mumbai, India
Category Company
Founded 1968
Sector Life Science
Employees24,006
Revenue 221.9B INR (2025)
DESCRIPTION

Lupin is an innovation-led transnational pharmaceutical company producing and developing a wide range of branded & generic formulations, APIs and biotechnology products. Lupin was founded in 1968 and is based in Mumbai, Maharashtra.

DEAL STATS #
Overall 11 of 11
Sector: Life Science M&A 9 of 9
Type: Add-on Acquisition M&A Deals 7 of 7
Country: United Kingdom M&A 1 of 1
Year: 2025 M&A 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2024-12-30 Eli Lilly - Huminsulin

Indianapolis, Indiana, United States

Eli Lilly's Huminsulin range of products is indicated for the treatment of type 1 and type 2 diabetes mellitus to improve blood sugar control in both adults and children.

Buy -
Mergr

Solution for

Product

Company

Legal